2026 Autoimmune hepatitis type 1 indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…

2026 Hepatitis E infection indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…

2026 Subacute sclerosing panencephalitis indication strategy covering epidemiology, Measles polymerase biology, active trials, transactions, unmet need,…

2026 Fusariosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Congenital rubella syndrome indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and…

2026 Scedosporiosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Mycetoma indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Dracunculiasis indication strategy covering epidemiology, Glutamate-gated chloride channel biology, active trials, transactions, unmet need, competition and…

2026 Chromoblastomycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Loiasis indication strategy covering epidemiology, Wolbachia biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Congenital toxoplasmosis indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…

2026 Visceral larva migrans indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market…